Dabigatran for percutaneous interventional cardiac catheterisation
AssigneeBoehringer Ingelheim Pharmaceuticals, Inc.
InventorPaul Anthony Reilly
Life of this patent
Estimating the term…
Abstract
The invention relates to a new use of dabigatran etexilate of formula (I) optionally in the form of the pharmaceutically acceptable salts thereof, and new medicament formulations which may be used for this purpose.
Claims10
A method to prevent coagulation in a patient undergoing percutaneous, interventional cardiac catheterization comprising the step of administering to the patient a compound of formula II
- optionally in the form of the tautomers, the pharmaceutically acceptable salts or prodrugs thereof prior to or during said catheterization.
6-8. (canceled)
A method to prevent coagulation in a patient undergoing percutaneous, interventional cardiac catheterization comprising the step of administering to the patient a pharmaceutical composition comprising a compound of formula I
- optionally in the form of the tautomers and the pharmaceutically acceptable salts thereof, prior to or during said catheterization.
Dependencies are inferred from the claim text.